loxl2b Antibody

What is LOXL2, and why is it targeted by antibodies in research?

LOXL2 (lysyl oxidase-like 2) is a copper-dependent enzyme that oxidizes lysine residues in collagen and elastin, enabling cross-linking and extracellular matrix (ECM) stabilization . Antibodies targeting LOXL2 are used to:

• Inhibit enzymatic activity (e.g., AB0023, an allosteric inhibitor)

• Track protein localization (e.g., in fibrotic tissues or cancer microenvironments)

• Study epigenetic regulation via histone H3K4me3 deamination

Basic vs. Advanced Focus

• For inhibition studies: Use AB0023, which binds remote from the catalytic site, enabling substrate-independent inhibition .

• For protein detection: Use ab96233 or CSB-RA907007A0HU, validated for multiple techniques .

How can I validate LOXL2 antibody specificity in my experimental system?

Validate specificity through:

• Positive Controls

  • Use recombinant LOXL2 or lysates from LOXL2-overexpressing cells.

• Negative Controls

  • Include LOXL2 knockdown/knockout samples (CRISPR or siRNA).

• Competitive Blocking

  • Pre-incubate antibody with immunizing peptide or recombinant LOXL2 to confirm epitope specificity .

Troubleshooting Cross-Reactivity

What experimental workflows should I use to study LOXL2’s dual roles in ECM remodeling and intracellular signaling?

LOXL2’s dual functions require tailored approaches:

ECM Remodeling Studies

• Collagen Cross-Linking Assays

  • Treat cells with AB0023 (1–10 µM) and measure collagen stiffness via atomic force microscopy .

• Fibrosis Models

  • Use Sirius Red staining to quantify collagen deposition in tissues treated with LOXL2 inhibitors .

Intracellular Signaling Studies

• Epigenetic Analysis

  • Perform ChIP-seq for H3K4me3 after LOXL2 knockdown to assess chromatin remodeling .

• EMT Pathway Profiling

  • Co-immunoprecipitate LOXL2 with SNAI1 or CBX5/HP1A to study chromatin interactions .

How does LOXL2 processing by proteases like FXa affect antibody binding?

LOXL2 is cleaved by serine proteases (e.g., FXa), generating a 65 kDa fragment . This impacts antibody utility:

Experimental Protocol for Processing Studies

• In Vitro Cleavage

  • Incubate recombinant LOXL2 with FXa (1 U/µg protein, 37°C, 1 hr).

• Western Blot

  • Use C-terminal (ab96233) and N-terminal (custom) antibodies to detect full-length and processed forms .

How do I interpret conflicting data on LOXL2’s role in cancer progression?

LOXL2’s context-dependent effects require nuanced analysis:

Data Reconciliation Strategy

• Tumor Subtype Analysis

  • Use TCGA data to correlate LOXL2 expression with immune/stromal scores in specific cancers (e.g., PAAD, LIHC) .

• Dual Inhibition Approaches

  • Combine LOXL2 inhibitors (AB0023) with checkpoint immunotherapies to dissect ECM vs. immune roles .

What are the limitations of using LOXL2 antibodies in preclinical models?

How can I optimize LOXL2 antibody performance in challenging samples (e.g., fibrotic liver or tumor tissues)?

What emerging techniques should I consider for LOXL2 antibody-based research?

• Single-Cell Proteomics

  • Use recombinant LOXL2 antibodies in mass cytometry to profile cellular heterogeneity in tumors .

• CRISPR-Cas9 Screening

  • Combine LOXL2 knockouts with antibody-based validation to identify synthetic lethal targets .

How do I design experiments to study LOXL2’s interaction with other fibrotic pathways (e.g., TGF-β)?

• Dual Inhibition

  • Treat fibrotic models with AB0023 (LOXL2 inhibitor) + TGF-β receptor kinase inhibitors.

• Proteomic Profiling

  • Perform IP-MS on LOXL2 immunoprecipitates to identify TGF-β pathway interactors .